1. Home
  2. NSYS vs VERU Comparison

NSYS vs VERU Comparison

Compare NSYS & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NSYS

Nortech Systems Incorporated

N/A

Current Price

$10.65

Market Cap

40.1M

Sector

Technology

ML Signal

N/A

Logo Veru Inc.

VERU

Veru Inc.

N/A

Current Price

$2.12

Market Cap

41.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NSYS
VERU
Founded
1981
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.1M
41.9M
IPO Year
1996
1996

Fundamental Metrics

Financial Performance
Metric
NSYS
VERU
Price
$10.65
$2.12
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $25.67
AVG Volume (30 Days)
5.4K
★ 145.2K
Earning Date
11-12-2026
12-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 80.85
N/A
EPS
★ 0.09
N/A
Revenue
$14,371,000.00
★ $16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$120.11
★ N/A
Revenue Growth
★ 7.01
N/A
52 Week Low
$6.74
$2.04
52 Week High
$18.01
$7.33

Technical Indicators

Market Signals
Indicator
NSYS
VERU
Relative Strength Index (RSI) 51.27 40.24
Support Level $9.91 N/A
Resistance Level $12.33 $2.68
Average True Range (ATR) 0.67 0.11
MACD 0.05 -0.00
Stochastic Oscillator 31.85 18.18

Price Performance

Historical Comparison
NSYS
VERU

About NSYS Nortech Systems Incorporated

Nortech Systems Inc is a United States-based electronic manufacturing services company. It offers value-added engineering, technical, and manufacturing services and support, including project management, design, testing, prototyping, manufacturing, supply chain management, and post-market services. The company's manufacturing and engineering services include complete medical devices, printed circuit board assemblies, wire and cable assemblies, and complex higher-level electro-mechanical assemblies. It operates in the Medical, Aerospace, Defense, and Industrial markets, with key revenue coming from medical-related markets.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: